Cargando…
An acute phase protein ready to go therapeutic for sepsis
The so-called Acute Phase Response (APR) begins between 12 and 48 h after the initiation of inflammation. This conserved response mainly involves the production of a set of Acute Phase Proteins (APPs) and the downregulation of other proteins (negative APPs) by hepatocytes. Although the precise ident...
Autores principales: | Vandevyver, Sofie, Dejager, Lien, Vandenbroucke, Roosmarijn E, Libert, Claude |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3936485/ https://www.ncbi.nlm.nih.gov/pubmed/24408964 http://dx.doi.org/10.1002/emmm.201303524 |
Ejemplares similares
-
The first MMP in sepsis
por: Vandenbroucke, Roosmarijn E, et al.
Publicado: (2011) -
TNFα cleavage beyond TACE/ADAM17: matrix metalloproteinase 13 is a potential therapeutic target in sepsis and colitis
por: Becker-Pauly, Christoph, et al.
Publicado: (2013) -
Human lung stem cells: Oh, the places you'll go!
por: Königshoff, Melanie, et al.
Publicado: (2011) -
Converting cancer mutations into therapeutic opportunities
por: O'Brien, Tom, et al.
Publicado: (2009) -
Novel non-coding RNA-based therapeutic approaches to prevent statin-induced liver damage
por: Bang, Claudia, et al.
Publicado: (2012)